Abstract：
UNASSIGNED: We presented the key findings from Singapore\'s Changi General Hospital Breast Centre\'s lymphedema surveillance strategy that used patients\' reported symptoms, standard arm circumference measurements and clinical assessment in the diagnosis of breast cancer-related lymphedema (BCRL). Our secondary aim was to highlight and discuss important elements of a surveillance strategy that can be implemented to track this outcome measure of breast cancer treatment for future research.
UNASSIGNED: We conducted a cross-sectional study of 511 breast cancer patients to assess the prevalence of BCRL and its associated risk factors. We defined BCRL prevalence rates based on patients\' self-reporting, objective arm circumference measure-ments and clinical diagnosis based on International Society of Lymphology (ISL) staging.
UNASSIGNED: The median follow-up of patients was 88.8 months. The cumulative prevalence rate in the cohort was 30.9%. The cohort of BCRL patients were older (58.4 versus [vs] 54.9 years), had higher mean Body Mass Index (27.7 vs 25.2), higher proportion of mastectomy (77% vs 64.3%), axillary clearance, less likely breast reconstruction, higher-grade tumour, more lymph nodes excised, more advanced nodal disease, and had undergone adjuvant chemotherapy. However, clinically apparent BCRL was only 6.5% (33 out of 511 patients). The proportion of clinically significant BCRL in patients undergoing sentinel lymph node biopsy (SLNB) or axillary sampling was 1.7% compared to 9.9% in patients who had undergone axillary clearance. Majority of the BCRL were subclinical or mild in severity.
UNASSIGNED: Our study showed that our rates of BCRL were comparable to international rates and highlighted similar patient profiles who were at risk of developing the disease. Having a comprehensive lymphedema surveillance strategy is paramount in paving the way for future studies.
UNASSIGNED: We conducted a cross-sectional study of 511 breast cancer patients to assess the prevalence of BCRL and its associated risk factors. We defined BCRL prevalence rates based on patients\' self-reporting, objective arm circumference measure-ments and clinical diagnosis based on International Society of Lymphology (ISL) staging.
UNASSIGNED: The median follow-up of patients was 88.8 months. The cumulative prevalence rate in the cohort was 30.9%. The cohort of BCRL patients were older (58.4 versus [vs] 54.9 years), had higher mean Body Mass Index (27.7 vs 25.2), higher proportion of mastectomy (77% vs 64.3%), axillary clearance, less likely breast reconstruction, higher-grade tumour, more lymph nodes excised, more advanced nodal disease, and had undergone adjuvant chemotherapy. However, clinically apparent BCRL was only 6.5% (33 out of 511 patients). The proportion of clinically significant BCRL in patients undergoing sentinel lymph node biopsy (SLNB) or axillary sampling was 1.7% compared to 9.9% in patients who had undergone axillary clearance. Majority of the BCRL were subclinical or mild in severity.
UNASSIGNED: Our study showed that our rates of BCRL were comparable to international rates and highlighted similar patient profiles who were at risk of developing the disease. Having a comprehensive lymphedema surveillance strategy is paramount in paving the way for future studies.
摘要：
■我们介绍了新加坡樟宜总医院乳腺中心淋巴水肿监测策略的主要发现，该策略使用了患者报告的症状，标准臂围测量和临床评估诊断乳腺癌相关淋巴水肿（BCRL）。我们的次要目的是强调和讨论可以实施的监测策略的重要元素，以跟踪乳腺癌治疗的结果指标，以供将来研究使用。
■我们对511名乳腺癌患者进行了一项横断面研究，以评估BCRL的患病率及其相关危险因素。我们根据患者的自我报告定义了BCRL患病率，基于国际淋巴学会（ISL）分期的客观臂围测量和临床诊断。
■患者的中位随访时间为88.8个月。队列中的累积患病率为30.9%。BCRL患者的队列年龄较大（58.4岁与[vs]54.9岁），平均体重指数较高（27.7vs25.2），乳房切除术的比例更高(77%vs64.3%)，腋窝间隙,乳房重建的可能性较小，高级别肿瘤，切除更多的淋巴结,更晚期的淋巴结疾病，并接受了辅助化疗。然而,临床上明显的BCRL仅为6.5%(511例患者中有33例).在接受前哨淋巴结活检（SLNB）或腋窝采样的患者中，具有临床意义的BCRL的比例为1.7％，而在接受腋窝清除的患者中为9.9％。大多数BCRL的严重程度为亚临床或轻度。
■我们的研究表明，我们的BCRL比率与国际比率相当，并强调了有患病风险的相似患者。拥有全面的淋巴水肿监测策略对于为未来的研究铺平道路至关重要。
■我们对511名乳腺癌患者进行了一项横断面研究，以评估BCRL的患病率及其相关危险因素。我们根据患者的自我报告定义了BCRL患病率，基于国际淋巴学会（ISL）分期的客观臂围测量和临床诊断。
■患者的中位随访时间为88.8个月。队列中的累积患病率为30.9%。BCRL患者的队列年龄较大（58.4岁与[vs]54.9岁），平均体重指数较高（27.7vs25.2），乳房切除术的比例更高(77%vs64.3%)，腋窝间隙,乳房重建的可能性较小，高级别肿瘤，切除更多的淋巴结,更晚期的淋巴结疾病，并接受了辅助化疗。然而,临床上明显的BCRL仅为6.5%(511例患者中有33例).在接受前哨淋巴结活检（SLNB）或腋窝采样的患者中，具有临床意义的BCRL的比例为1.7％，而在接受腋窝清除的患者中为9.9％。大多数BCRL的严重程度为亚临床或轻度。
■我们的研究表明，我们的BCRL比率与国际比率相当，并强调了有患病风险的相似患者。拥有全面的淋巴水肿监测策略对于为未来的研究铺平道路至关重要。
